Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Citi
US Department of Justice
Accenture
Farmers Insurance
Cantor Fitzgerald
Federal Trade Commission
Fuji
Moodys
US Army

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,962,603

« Back to Dashboard

Which drugs does patent 8,962,603 protect, and when does it expire?

Patent 8,962,603 protects ELLA and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 8,962,603
Title:Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.
Inventor(s): Levy; Delphine (Paris, FR), Ulmann; Andre (Paris, FR), Mathe; Henri Camille (Paris, FR), Gainer; Erin (Paris, FR)
Assignee: Laboratoire HRA-Pharma (Paris, FR)
Application Number:13/575,086
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,962,603

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHTHAVING A BMI OF 25 TO 29.99 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,962,603

PCT Information
PCT FiledDecember 01, 2010PCT Application Number:PCT/EP2010/068646
PCT Publication Date:August 04, 2011PCT Publication Number: WO2011/091890

International Patents Family Members for US Patent 8,962,603

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2011091890 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Boehringer Ingelheim
Harvard Business School
Dow
Farmers Insurance
Teva
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot